BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics


BioXcel Therapeutics, Inc. (BTAI)

Today's Latest Price: $47.72 USD

1.39 (-2.83%)

Updated Jun 5 4:00pm

Add BTAI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BTAI Daily Price Range
BTAI 52-Week Price Range

BTAI Stock Price Chart More Charts


BTAI Price/Volume Stats

Current price $47.72 52-week high $53.10
Prev. close $49.11 52-week low $3.76
Day low $47.31 Volume 257,159
Day high $51.30 Avg. volume 576,635
50-day MA $35.20 Dividend yield N/A
200-day MA $18.65 Market Cap 964.47M

BioXcel Therapeutics, Inc. (BTAI) Company Bio


BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.


BTAI Latest News Stream


Event/TimeNews Detail
Loading, please wait...

BTAI Latest Social Stream


Loading social stream, please wait...

View Full BTAI Social Stream

Latest BTAI News From Around the Web

Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity.

Benzinga's Top Upgrades, Downgrades For June 4, 2020

Upgrades * For American Eagle Outfitters Inc (NYSE: AEO), Morgan Stanley upgraded the stock from Underweight to Equal-Weight. For the first quarter, American Eagle Outfitters had an EPS of ($0.84), compared to year-ago quarter EPS of $0.24. The stock has a 52-week-high of $19.90 and a 52-week-low of $6.54. American Eagle Outfitters's stock last closed at $11.81 per share. * For Comerica Inc (NYSE: CMA), B. Riley FBR upgraded the stock from Neutral to Buy. In the first quarter, Comerica showed an EPS of ($0.46), compared to $2.08 from the year-ago quarter. The stock has a 52-week-high of $74.11 and a 52-week-low of $24.28. Comerica's stock last closed at $40.04 per share. * Oppenheimer upgraded the stock for Sally Beauty Holdings Inc (NYSE: SBH) from Perform to Outperform. Sally Beau...

Yahoo | June 4, 2020

BioXcel Therapeutics to Present at the Jefferies Virtual Healthcare Conference

NEW HAVEN, Conn., May 28, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.

Yahoo | May 28, 2020

The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) ChemoCentryx Inc (NASDAQ: CCXI ) Evoke Pharma Inc (NASDAQ: EVOK ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Translate Bio Inc (NASDAQ: TBIO ) Twist Bioscience Corp (NASDAQ: TWST ) United Therapeutics Corporation (NASDAQ: UTHR ) VBI Vaccines Inc (NASDAQ: VBIV ) Vermillion, Inc. (NASDAQ: VRML ) Zai...

Benzinga | May 20, 2020

The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therape...

Benzinga | May 19, 2020

The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) Allogene Therapeutics Inc (NASDAQ: ALLO )(reacted to ASCO abstract ) Altimmune Inc (NASDAQ: ALT )(announced first-quarter results and update to its COVID-19 vaccine program) BioXcel Therapeutics Inc (NASDAQ: BTAI )( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) Co-Diagnostics Inc (NASDAQ: CODX ) Myokardia Inc (NASDAQ: MYOK ) Repligen Corporation (NASDAQ: RGEN ) Translate Bio Inc (NASDAQ: TBIO ) VBI Vaccines Inc (NASDAQ: VBIV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows M...

Benzinga | May 15, 2020

Read More 'BTAI' Stories Here

BTAI Price Returns

1-mo 25.35%
3-mo 44.34%
6-mo 674.68%
1-year 335.80%
3-year N/A
5-year N/A
YTD 226.63%
2019 278.50%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6665 seconds.